We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+15.01%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$115M
AUM Growth
+$35.6M
Cap. Flow
+$33.1M
Cap. Flow %
28.7%
Top 10 Hldgs %
16.88%
Holding
267
New
23
Increased
109
Reduced
60
Closed
21

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.39M
2
INDA icon
iShares MSCI India ETF
INDA
+$872K
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$767K
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$708K
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$648K

Top Sells

Rank Stock Value
1
UPW icon
ProShares Ultra Utilities
UPW
+$1.11M
2
VDE icon
Vanguard Energy ETF
VDE
+$755K
3
RXDX
Ignyta, Inc.
RXDX
+$612K
4
FTEC icon
Fidelity MSCI Information Technology Index ETF
FTEC
+$430K
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$359K

Sector Composition

Rank Sector Weight
1 Healthcare 78.8%
2 Financials 0.81%
3 Technology 0.51%
4 Consumer Discretionary 0.44%
5 Communication Services 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLT icon
1
iShares 20+ Year Treasury Bond ETF
TLT
$42.5B
$3.32M 2.88%
27,200
+11,511
+73% +$1.39M
FTEC icon
2
Fidelity MSCI Information Technology Index ETF
FTEC
$20B
$3.22M 2.79%
62,005
-8,112
-12% -$430K
VPU
3
Vanguard Utilities ETF
VPU
$8.62B
$2.55M 2.22%
22,845
-225
-1% -$24.8K
GERN icon
4
Geron
GERN
$917M
$1.61M 1.4%
379,430
+204,747
+117% +$553K
NKTR icon
5
Nektar Therapeutics
NKTR
$2.22B
$1.59M 1.38%
1,001
-125
-11% -$161K
IOVA icon
6
Iovance Biotherapeutics
IOVA
$2.2B
$1.54M 1.33%
90,926
+50,667
+126% +$767K
FAS icon
7
Direxion Daily Financial Bull 3x ETF
FAS
$2.4B
$1.51M 1.31%
23,570
+117
+0.5% +$8.35K
GTHX
8
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.41M 1.23%
38,125
+20,478
+116% +$546K
ONC
9
BeOne Medicines Ltd
ONC
$32.4B
$1.36M 1.18%
8,082
+4,349
+117% +$589K
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.33M 1.16%
20,024
-1,172
-6% -$67.7K
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.32M 1.15%
43,136
+23,350
+118% +$648K
JNCE
12
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.32M 1.14%
58,867
+31,919
+118% +$708K
TGTX icon
13
TG Therapeutics
TGTX
$8.36B
$1.28M 1.11%
89,920
+48,087
+115% +$615K
PTCT icon
14
PTC Therapeutics
PTCT
$6.44B
$1.27M 1.1%
46,917
+25,165
+116% +$638K
ENTA icon
15
Enanta Pharmaceuticals
ENTA
$380M
$1.26M 1.1%
15,613
-1,918
-11% -$148K
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.24M 1.08%
68,484
-4,063
-6% -$67.7K
INDA icon
17
iShares MSCI India ETF
INDA
$6.81B
$1.24M 1.08%
36,402
+24,558
+207% +$872K
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.81B
$1.22M 1.06%
16,409
-1,488
-8% -$99.2K
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
$1.21M 1.05%
93,317
+50,832
+120% +$632K
NVAX icon
20
Novavax
NVAX
$1.31B
$1.19M 1.03%
28,227
+14,967
+113% +$601K
IMGN
21
DELISTED
Immunogen Inc
IMGN
$1.18M 1.03%
112,547
+58,570
+109% +$579K
AGIO icon
22
Agios Pharmaceuticals
AGIO
$2.38B
$1.18M 1.02%
14,405
+7,781
+117% +$601K
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.13M 0.98%
9,629
+5,247
+120% +$648K
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$1.12M 0.97%
68,763
+36,645
+114% +$587K
LGND icon
25
Ligand Pharmaceuticals
LGND
$6.01B
$1.12M 0.97%
10,854
-625
-5% -$61.8K
1
2 3 4 5

Similar funds

AMIM
Aull & Monroe Investment Management Mobile, Alabama $215M AUM 28.37% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $215M AUM 6.73% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
OC
Optima Capital Beaverton, Oregon $215M AUM 17.28% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return

Virtus ETF Advisers's Q1 2018 Portfolio in Review

As of Q1 2018, Virtus ETF Advisers held 267 positions worth $115M, up 45% from $79.7M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Virtus ETF Advisers deployed $33.1M of net new capital in Q1 2018, opening 23 new positions and adding to 109 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Vanguard Energy ETF, an estimated $755K trimmed.

  • Virtus ETF Advisers's largest Q1 2018 buy was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q1 2018, an estimated $1.39M increase.
  • Virtus ETF Advisers's biggest Q1 2018 reduction was Vanguard Energy ETF, cutting an estimated $755K.
  • Virtus ETF Advisers fully exited ProShares Ultra Utilities in Q1 2018, selling an estimated $1.11M.
  • Virtus ETF Advisers's ten largest holdings make up 17% of its $115M portfolio in Q1 2018.
  • Virtus ETF Advisers opened 23 new positions and closed 21 in Q1 2018.
  • Virtus ETF Advisers's portfolio value rose 45% quarter-over-quarter to $115M.

Based on Virtus ETF Advisers's 13F filing for Q1 2018, filed 14 May 2018.